COGNITION THERAPEUTICS

Cognition Therapeutics Presents Poster of Participant Demographics from Phase 2 Dementia with Lewy Bodies Study at CTAD

31 أكتوبر 2024 15:15:00 بحسب Nasdaq GlobeNewswire

Cognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD

29 أكتوبر 2024 11:55:00 بحسب Nasdaq GlobeNewswire

Analyses from Cognition’s Positive Phase 2 ‘SHINE’ Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease will be Presented in a Podium Presentation at CTAD

23 أكتوبر 2024 06:30:27 بحسب Nasdaq GlobeNewswire

Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Executing Clinical Research in Dementia with Lewy Bodies (DLB)

22 أكتوبر 2024 06:30:00 بحسب Nasdaq GlobeNewswire

Cognition Therapeutics Will Participate in the Roth Healthcare Opportunities Conference

02 أكتوبر 2024 06:30:00 بحسب Nasdaq GlobeNewswire

Cognition Therapeutics Supports Lewy Body Dementia Awareness Month and the Need for Improved Treatments for the Second Most Common Dementia

01 أكتوبر 2024 06:30:00 بحسب Nasdaq GlobeNewswire

Cognition Therapeutics to Participate in Upcoming September 2024 Investor Conferences

03 سبتمبر 2024 06:30:00 بحسب Nasdaq GlobeNewswire

Cognition Therapeutics Publishes EEG Findings from Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease

22 أغسطس 2024 06:31:24 بحسب Nasdaq GlobeNewswire

Cognition Therapeutics Reports Financial Results for the Second Quarter 2024 and Provides Business and Clinical Update

08 أغسطس 2024 06:00:53 بحسب Nasdaq GlobeNewswire

Cognition Therapeutics to Report Second Quarter 2024 Financial Results

05 أغسطس 2024 06:30:19 بحسب Nasdaq GlobeNewswire

Cognition Therapeutics’ Proof-of-Concept Phase 2 SHINE Trial Demonstrates Consistent Improvement in Cognitive Outcomes with Once-Daily Oral CT1812 in Mild-to-Moderate Alzheimer’s Patients

29 يوليو 2024 06:00:33 بحسب Nasdaq GlobeNewswire

Cognition Therapeutics to Host Investor Webcast to Discuss Results from Proof-of-Concept Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease at 8:30am ET on Monday July 29, 2024

26 يوليو 2024 15:11:52 بحسب Nasdaq GlobeNewswire

Results from Cognition Therapeutics’ Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease Accepted for Presentation at AAIC

02 يوليو 2024 06:30:38 بحسب Nasdaq GlobeNewswire

Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Protecting the Synapse from Amyloid Toxicity in Alzheimer's Disease

21 مايو 2024 06:30:00 بحسب Nasdaq GlobeNewswire

Cognition Therapeutics Reports Financial Results for the First Quarter 2024 and Provides Business Update

07 مايو 2024 06:30:00 بحسب Nasdaq GlobeNewswire

Cognition Therapeutics Completes Enrollment in Phase 2 SHIMMER Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies

29 أبريل 2024 06:30:57 بحسب Nasdaq GlobeNewswire

Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer’s Disease

22 أبريل 2024 06:30:22 بحسب Nasdaq GlobeNewswire

Cognition Therapeutics to Present at the Needham Virtual Healthcare Conference

02 أبريل 2024 06:30:47 بحسب Nasdaq GlobeNewswire

Cognition Therapeutics to host Virtual KOL Event on the Evolving Landscape in Alzheimer’s Disease on April 12, 2024

01 أبريل 2024 06:30:39 بحسب Nasdaq GlobeNewswire

Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update

26 مارس 2024 06:00:56 بحسب Nasdaq GlobeNewswire